This company has been marked as potentially delisted and may not be actively trading. Cogent Biosciences (UMRX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock UMRX vs. CALT, ZYME, MENS, SBTX, MBX, AVTE, NLTX, CYBN, BIOA, and WHWKShould you be buying Cogent Biosciences stock or one of its competitors? The main competitors of Cogent Biosciences include Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Jyong Biotech (MENS), Silverback Therapeutics (SBTX), MBX Biosciences (MBX), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), Cybin (CYBN), BioAge Labs (BIOA), and Whitehawk Therapeutics (WHWK). Cogent Biosciences vs. Its Competitors Calliditas Therapeutics AB (publ) Zymeworks Jyong Biotech Silverback Therapeutics MBX Biosciences Aerovate Therapeutics Neoleukin Therapeutics Cybin BioAge Labs Whitehawk Therapeutics Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Cogent Biosciences (NASDAQ:UMRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability. Which has more risk and volatility, CALT or UMRX? Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Comparatively, Cogent Biosciences has a beta of 3.93, indicating that its share price is 293% more volatile than the S&P 500. Do insiders and institutionals have more ownership in CALT or UMRX? 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 26.4% of Cogent Biosciences shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Comparatively, 31.5% of Cogent Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has better valuation and earnings, CALT or UMRX? Cogent Biosciences has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62Cogent Biosciences$22.50M21.52-$31.83M-$1.04-10.96 Is CALT or UMRX more profitable? Calliditas Therapeutics AB (publ) has a net margin of -30.18% compared to Cogent Biosciences' net margin of -96.84%. Cogent Biosciences' return on equity of -87.78% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96% Cogent Biosciences -96.84%-87.78%-52.14% Does the media favor CALT or UMRX? In the previous week, Calliditas Therapeutics AB (publ)'s average media sentiment score of 0.00 equaled Cogent Biosciences'average media sentiment score. Company Overall Sentiment Calliditas Therapeutics AB (publ) Neutral Cogent Biosciences Neutral SummaryCogent Biosciences beats Calliditas Therapeutics AB (publ) on 8 of the 11 factors compared between the two stocks. Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for UMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UMRX vs. The Competition Export to ExcelMetricCogent BiosciencesPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$484.15M$724.08M$5.52B$9.35BDividend YieldN/A4.84%4.74%4.14%P/E Ratio-15.001.3729.0523.78Price / Sales21.5225.69444.6497.50Price / CashN/A19.5624.4827.20Price / Book10.966.688.365.61Net Income-$31.83M-$3.67M$3.25B$265.26M Cogent Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UMRXCogent BiosciencesN/A$11.40-0.2%N/A+21.3%$484.15M$22.50M-15.0072CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ZYMEZymeworks3.0201 of 5 stars$14.41+0.6%$21.00+45.8%+23.2%$1.01B$93.38M-9.62460Upcoming EarningsMENSJyong BiotechN/A$11.50+14.3%N/AN/A$874.35MN/A0.0031SBTXSilverback TherapeuticsN/A$17.59-1.5%N/A+73.5%$634.26MN/A-7.2783High Trading VolumeMBXMBX Biosciences1.9082 of 5 stars$12.60+7.7%$37.57+198.1%N/A$425.66MN/A0.0036AVTEAerovate TherapeuticsN/A$8.98+3.3%N/A-88.6%$260.29MN/A-3.0020Upcoming EarningsHigh Trading VolumeNLTXNeoleukin TherapeuticsN/A$22.34-1.2%N/A-44.9%$209.95MN/A-7.1890Gap DownHigh Trading VolumeCYBNCybin2.8392 of 5 stars$7.93+2.6%$85.00+971.9%N/A$183.50MN/A-1.8250News CoveragePositive NewsBIOABioAge LabsN/A$4.77+0.2%N/AN/A$171.00MN/A0.00N/APositive NewsWHWKWhitehawk TherapeuticsN/A$1.93+3.2%N/AN/A$90.92M$25.98M12.0640Gap Up Related Companies and Tools Related Companies CALT Alternatives ZYME Alternatives MENS Alternatives SBTX Alternatives MBX Alternatives AVTE Alternatives NLTX Alternatives CYBN Alternatives BIOA Alternatives WHWK Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UMRX) was last updated on 8/4/2025 by MarketBeat.com Staff From Our PartnersCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWall Street Laughed. Now They're Buying.For six months, I’ve been pounding the table on a major gold miner—while Twitter pundits laughed. But now, the...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Create New Advertiser | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
